摘要 : Aim: This phase II study investigated safety and efficacy of dilpacimab or bevacizumab plus FOLFIRI in patients with previously treated metastatic colorectal cancer (mCRC). Materials & methods: Overall, 66 patients were treated (n... 展开
作者 | Strickler~ John H. Cubillo~ Antonio Liang~ Jin-Tung Matrana~ Marc Kozloff~ Mark Lowe~ Thomas Blaney~ Martha Sahtout~ Mohammad Naumovski~ Louie Wainberg~ Zev A. |
---|---|
作者单位 | |
期刊名称 | 《Future oncology》 |
总页数 | 10 |
语种/中图分类号 | 英语 / R73 |
关键词 | bevacizumab colorectal cancer dilpacimab DLL4 FOLFIRI FLUOROURACIL OXALIPLATIN COMBINATION LEUCOVORIN AFLIBERCEPT IRINOTECAN PLACEBO GROWTH DLL4 VEGF |
馆藏号 | N2009EPST0001601 |